Jordana Jampel

DocwireNews

A group of researchers from Lund University conducted the MASAI trial within the Swedish national screening program. The aim of this randomized, controlled, parallel-group, noninferiority, single-blinded, screening-accuracy study was to assess the use of artificial intelligence (AI) to reduce the screen-reading workload and increase cancer detection without a significant increase in false-positive results. Findings were <a href="https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00267-X/fulltext">published</a> in The Lancet Digital Health.
In this trial, AI was used to triage examinations to single or double reading depending on the AI risk score and as detection support for radiologists by highlighting imaging findings suggestive of disease. The inclusion criterion was eligibility for participation in population-based mammography screening, which includes women aged 40-74 years; no exclusion criteria were applied. The primary outcome is the interval cancer rate to be assessed after at least 2 years of follow-up, starting in December 2024 and for the next 6 months to ensure inclusion of all reported participant data.
Between April 2021 and December 2022, 106,106 women presented for screening, and 172 opted out of the trial; 105,934 participants were randomly assigned 1:1 to either AI-supported screening (intervention group, n=53,052) or a standard double reading group without AI (control group, n=52,882).
There was a 29% increase in cancer detection with AI-supported screening. In the intervention group, 941 (84.4%) women were recalled because of mammographic findings versus 847 (82.5%) in the control group. There were 48,444 fewer screen readings and 65 more consensus meetings in the intervention group than in the control group, which is a 44.2% reduction in the screen-reading workload.
Of note, there were only seven more false-positive results in the intervention group than in the control group, at 772 (1.5%) and 765 (1.4%), respectively, with P=.92.
“The use of AI did not negatively influence the rates of recalls, false positives, or consensus meetings and the screen-reading workload was reduced by almost half,” the researchers concluded.
Source
<a href="https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00267-X/fulltext">The Lancet Digital Health</a>

Rob Dillard

Updated Guidance: Athletes With Certain Heart Conditions Are Able to Play Competitive Sports

Heart Failure

Stephen V. Liu, MD

Cecilia Brown

Stephen Liu, MD, Shares Insights on the eNRGy Trial

Non-Small Cell Lung Cancer

Emily Menendez

ctDNA Detection Outperforms Standard Surveillance in Predicting BTC Recurrence

Bile Duct Cancer

Latest News

AI Screening Accuracy in MASAI Trial Reduced Screen-Reading Time for Mammography

Breast Cancer News

There was a 29% increase in cancer detection with AI-supported screening.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe